[Show abstract][Hide abstract] ABSTRACT: Objectives: To investigate the effects of zinc supplementation on pregnancy outcome in patients with gestational diabetes mellitus.
Methodology: During the randomized double blind clinical trial 60 women with gestational diabetes mellitus from 32nd of gestational age were assigned to two equal groups to receive 25mg zinc sulfate orally per day as case or placebo as control. Then, groups were compared regarding insulin dosage needs, macrosomia and preeclampsia.
Results: Insulin requirements and dosage changes during the investigation were lower in the case group than in the control (P < 0.001). Women in the zinc supplemental group had a lower percentage of large infants compared to control (P < 0.01). There were no significant differences between two groups regarding the rates of preeclampsia and cesarean delivery.
Conclusions: This study showed that zinc supplementation in gestational diabetes could reduce insulin needs and improve glycemic control of these patients and it may also reduce macrosomia.
Pakistan Journal of Medical Sciences Online 08/2011; 27(5):1203-1206. · 0.10 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The purpose of this study was to compare the efficacy and side effects of two different misoprostol regimens for second-trimester pregnancy termination. Sixty women in second trimester of gestation with indications for pregnancy termination were randomly assigned in two equal groups to receive either vaginal or oral misoprostol. The dosing regimen was 400 microg as the initial dose followed by 400 microg up to 3 doses (1200 microg) if needed in each group. Efficacy and side effects were compared. The percentage of women who delivered was significantly higher in vaginal group than the oral group (86.7 vs. 43.3 p = 0.0006). No significant differences in complication rates and induction to delivery interval were noted between the two groups. Vaginal administration of misoprostol resulted in a higher success rate for second trimester pregnancy termination, whereas, no significant differences in induction to delivery time and complication rates were noted between vaginal and oral groups.
Pakistan Journal of Biological Sciences 12/2008; 11(21):2505-8.
[Show abstract][Hide abstract] ABSTRACT: To compare the efficacy and complications of intravaginal Misoprostol with oxytocin for induction of labor this study was carried out. One hundred and ten term pregnant women with Bishop score of < or = 4 were randomized into two groups. Fifty five patients received 50 microg intravaginal Misoprostol 2 times at 6 h intervals (Misoprostol group), the second group received oxytocin infusion (6 mu min(-1)) for induction of labor (oxytocin group n = 55). The time from induction to delivery, the route of delivery, fetal outcome and maternal complications were recorded. There was no statistically significant difference regarding demographic or clinical characteristics between two groups. Induction success within the first 12 h were 80 and 33.3% for Misoprostol and oxytocin groups respectively (p<0.05). The average time from induction to delivery was 10. 6 +/- 3.7 and 17 +/- 7.2 h in the Misoprostol and oxytocin administered groups, respectively (p<0.05). The rate of vaginal delivery was significantly higher in misoprostol group (72.7%) when compared with oxytocin group (45.5%). Low Apgar score, meconium stain amniotic fluid, abnormal FHR and precipitating labor was similar in both groups (p>0.05). We concluded misoprostol 50 microg vaginally (every 6 h, up to 100 microg) safely and effectively induces labor and it is recommended for parturient women with Bishop score < or = 4 and the use of this drug could produce several beneficial effects, particularly a decrease in the incidence of cesarean delivery.
Pakistan Journal of Biological Sciences 03/2007; 10(6):920-3.
[Show abstract][Hide abstract] ABSTRACT: To compare misoprostol with curettage in termination of missed abortion (up to 12 week`s conception) this study was designed. Eighty women with missed abortion were assigned after random list to be treated with 800 mcg misoprostol intravaginally first and then 400 mcg q.4.h up to 3 doses if was needed (Medical group n = 40) or dilation and sharp curettage (Surgical group n = 40) for terminating of first trimester missed abortion. Thirty five cases (87.5%) in medical group had complete abortion without any need to curettage and in 37 cases (92.5%) in surgical group the uterus was evacuated completely by sharp curettage. This difference was not statistically significant. Duration of bleeding in medical group was significantly more than surgical group. There was no significant difference in hemoglobin level after abortion between two groups. The most complications in medical group were lower abdominal pain and fever. We concluded misoprostol 800 mcg intravaginally (400 mcg q.4.h up to 3 doses, if needed) may offer an efficacious and safe alternative to the surgery and we recommend this method for terminating of first trimester missed abortion.